SUTRO BIOPHARMA, INC.

(STRO)
  Report
Delayed Nasdaq  -  04:00 2022-08-15 pm EDT
7.110 USD   +0.28%
08/10TRANSCRIPT : Sutro Biopharma, Inc. Presents at 13th Annual Wedbush PacGrow Healthcare Conference 2022, Aug-10-2022 02:20 PM
CI
08/09Berenberg Bank Adjusts Sutro Biopharma's Price Target to $26 From $30, Maintains Buy Rating
MT
08/08SUTRO BIOPHARMA : Reports Second Quarter 2022 Financial Results, Business Highlights and Anticipated Milestones - Form 8-K
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sutro Biopharma : Open Letter from CEO, Bill Newell

03/31/2021 | 09:57pm EDT

I want to address the violence and discrimination towards our AAPI community; it has been there for hundreds of years. It is now apparent that it was, in some cases, under-reported or ignored. Most certainly it was greatly under-appreciated. However, recent news coverage of these reprehensible attacks and the resulting amplification of this evidence of violence have shown a constant spotlight on what seems to be daily instances of violence and discrimination.

We live and work in the Bay Area. We are blessed with a thriving Asian community. This community is an integral part of our Bay Area and of our Sutro identity. I have lived in ignorance about what can only be characterized as a dark underbelly of violence and discrimination against our AAPI community. I regret that I wasn't more sensitized to these issues.

My friend and fellow Kilimanjaro climber, Nancy Hong, published an Op Ed today in the Timmerman Report. She has captured more eloquently than I the essence of these issues. I especially appreciate her biotech perspective. I hope you will take a moment to read this article; her views represent my own; and I stand in support of finding solutions to end violence and racism aimed at the AAPI community: https://timmermanreport.com/2021/03/asian-americans-in-biotech-breaking-the-silence/

As encouraged by Nancy, I have added my name as Sutro's CEO to join with other leaders in supporting www.standwithasianamericans.com and I have also made a personal donation to the Asian Pacific Fund. Clearly there is more to be done to address this assault on our AAPI community, but it is important we be on record as not tolerating this racism and violence. I look forward to engaging with our Diversity, Equity, Inclusion & Belonging team to find other ways that we at Sutro can stand up and be counted.We cannot be and will not be silent any longer.

Disclaimer

Sutro Biopharma Inc. published this content on 31 March 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 April 2021 01:29:04 UTC.


© Publicnow 2021
All news about SUTRO BIOPHARMA, INC.
08/10TRANSCRIPT : Sutro Biopharma, Inc. Presents at 13th Annual Wedbush PacGrow Healthcare Conf..
CI
08/09Berenberg Bank Adjusts Sutro Biopharma's Price Target to $26 From $30, Maintains Buy Ra..
MT
08/08SUTRO BIOPHARMA : Reports Second Quarter 2022 Financial Results, Business Highlights and A..
PU
08/08SUTRO BIOPHARMA, INC. Management's Discussion and Analysis of Financial Condition and ..
AQ
08/08Sutro Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months En..
CI
08/08Earnings Flash (STRO) SUTRO BIOPHARMA Posts Q2 Revenue $28.1M
MT
08/08Sutro Biopharma Reports Second Quarter 2022 Financial Results, Business Highlights and ..
AQ
08/03Sutro Biopharma to Present at the 2022 Wedbush PacGrow Healthcare Conference
AQ
07/27Sutro Biopharma Achieves 'First in Human' Milestone in Cytokine Derivatives Collaborati..
AQ
07/26SUTRO BIOPHARMA, INC. : Other Events (form 8-K)
AQ
More news
Analyst Recommendations on SUTRO BIOPHARMA, INC.
More recommendations
Financials (USD)
Sales 2022 76,5 M - -
Net income 2022 -121 M - -
Net cash 2022 166 M - -
P/E ratio 2022 -2,76x
Yield 2022 -
Capitalization 371 M 371 M -
EV / Sales 2022 2,68x
EV / Sales 2023 5,39x
Nbr of Employees 242
Free-Float 89,7%
Chart SUTRO BIOPHARMA, INC.
Duration : Period :
Sutro Biopharma, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SUTRO BIOPHARMA, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 7,11 $
Average target price 26,50 $
Spread / Average Target 273%
EPS Revisions
Managers and Directors
William J. Newell President, Chief Executive Officer & Director
Edward C. Albini Chief Financial Officer & Secretary
Connie L. Matsui Chairman
Henry Heinsohn Vice President-Technology & Innovation
Trevor Hallam Chief Scientific Officer & President-Research
Sector and Competitors
1st jan.Capi. (M$)
SUTRO BIOPHARMA, INC.-52.22%370
GILEAD SCIENCES, INC.-8.81%78 912
VERTEX PHARMACEUTICALS39.13%75 532
REGENERON PHARMACEUTICALS, INC.1.86%67 214
WUXI APPTEC CO., LTD.-20.33%40 830
BIONTECH SE-36.97%38 968